Free Hormone Therapy in BC Is Welcome News. Here’s How to Make the Most of It.
What the new PharmaCare coverage means for women in perimenopause and menopause — and where personalized clinical care helps bridge the outcomes
Something meaningful shifted in BC this spring. As of March 1, 2026, select menopausal hormone therapy medications are now fully covered at no cost under the National Pharmacare Plan — no deductible, no dispensing fee, for any BC resident enrolled in MSP. [1] For women who've been managing symptoms while absorbing costs of up to $1,800 a year, that's a real change. [2]
And it applies to women in perimenopause too — not just those who've reached menopause. If hormones are fluctuating, periods are irregular, and symptoms are affecting your daily life in perimenopause, you can still access coverage. If hormone therapy is clinically appropriate for you, these medications are available wherever you are in the transition.
This is genuinely good news. It also opens up a conversation worth having — about what coverage provides, what individualized care adds, and how to make sure what you're taking is actually working for you.
A prescription that costs nothing still needs to be the right prescription.
What's Covered
Plan NP covers a meaningful selection of commonly used hormone therapies — oral and transdermal estrogen options, progesterone, vaginal estrogen for genitourinary symptoms, and combination products. The complete list of covered medications, with specific formulations and brands, is available directly from BC PharmaCare at www2.gov.bc.ca/pharmacare/plan-np-mht. Your pharmacist can confirm coverage at the counter and, in most cases, suggest a covered equivalent if your specific prescription isn't on the list.
No prior approval or referral is needed for any covered menopause hormone therapy (MHT) — your prescriber writes the prescription and you fill it. [1]
Where Personalized Guidance Still Makes a Difference
Coverage opens the door. A personalized care plan is what helps you walk through it confidently. For women in perimenopause and menopause, some of the most meaningful clinical decisions involve options and nuances that a coverage list alone can't navigate for you.
The covered options are a starting point — your needs may go further
Plan NP covers a strong selection of commonly used formulations, and for many women that will be exactly what's needed. For others, the best clinical fit involves options outside the covered list — like Duavive (conjugated estrogens/bazedoxifene), a hormone therapy that uses a selective estrogen receptor modulator in place of traditional progestogen for endometrial protection, which is not currently a listed Plan NP benefit. [3] Knowing which option is right for your health history and symptom picture is what a clinical assessment is for.
The non-hormonal landscape is growing
For women who prefer or need a hormone-free approach, the options have expanded meaningfully. Two non-hormonal treatments have recently received Health Canada approval — Veozah (fezolinetant), approved December 2024, and Lynkuet (elinzanetant), approved July 2025 — both indicated for moderate-to-severe vasomotor symptoms associated with menopause. [4] [5] Lynkuet has also shown benefit for sleep disruption alongside hot flash relief, which is a meaningful advantage for many women in the menopausal transition. Neither is covered under Plan NP, but both represent real, evidence-based options for women for whom hormone therapy isn't the right path. A provider current on the evidence can help you understand whether either belongs in your plan, and should discuss the additional non-hormonal evidence-based and guideline supported options available.
Testosterone and other options are part of the conversation too
Testosterone can be an important part of midlife care for some women — particularly for those with a diagnosis of low sexual desire disorder — but there is no Health Canada–approved formulation specifically for women, and it falls outside Plan NP coverage. [6] A range of other prescription options also exists for specific symptoms. These are conversations that benefit from a provider who has the time and the clinical focus to explore them properly — as part of a whole picture, not a brief aside.
What Personalized Care Adds
Perimenopause in particular is not a straight line. Estrogen levels don't decline smoothly — they fluctuate unpredictably for years before stabilizing. A woman at 44 may need a different approach than she does at 49, and what's working in the first year of treatment may benefit from recalibration in the second. This is the nature of the transition, not a problem with the treatment.
What personalized care adds is the clinical judgment to navigate it well — knowing which formulation matches your symptom pattern, which delivery method suits your health history, how to read your body's response in the early months, and how to adjust thoughtfully as your hormonal environment continues to shift. These are clinical questions that benefit from clinical answers, and from a provider who has both the time and the expertise to engage with them over time.
Any provider can prescribe menopausal hormone therapy — that's not the distinction. What makes a difference is the combination of dedicated training, certification, and a practice built entirely around midlife women's health. The Menopause Society Certified Practitioner (MSCP) credential reflects that additional layer of expertise. And a practice focused exclusively on this stage of life brings something a general clinical encounter can't always offer: the time, the current evidence, and the whole-person context to navigate it well.
Coverage brings the medication within reach. Personalized care plans bring the outcomes.
A prescription is only a tool within the midlife care strategy. And like any tool, its value depends entirely on how it's used. The right medication at the wrong dose, or for the wrong stage of transition, or without the lifestyle and metabolic context that determines how well it works, won't deliver the outcomes a woman is hoping for.
Effective care in perimenopause and menopause brings together hormone therapy, nutrition, sleep, stress physiology, movement, and long-term health priorities like bone, heart, and brain health — as a coherent longitudinal plan, not a series of separate brief fragmented conversations. The prescription sits within that plan. It doesn't replace it.
What specialist menopause care offers is the full landscape of options, the clinical judgment to match them to your situation, and a partner in your care who follows your response over time and adjusts with you.
Your Next Step
If you're in perimenopause or menopause and cost has been one of the reasons you haven't yet pursued care, this coverage change is a meaningful moment to pause and consider your options. The medications on the covered list are real, accessible, and clinically valuable.
And if you've already filled a prescription but still don't quite feel like yourself — or if you're simply wondering whether what you're taking is the best fit for where you are — that's exactly the kind of question individualized care is built to answer.
At RoseWell Health, we work with women across British Columbia at every stage of perimenopause and menopause — building care plans grounded in your full clinical picture, your symptoms, and your goals. We'll help you understand what's covered, what else is available, and what makes the most sense for you.
Book your Intake & Consultation at RoseWell Health. Select medications may now be free. Getting the most from all options — that's what we're here for.
References
[1] BC Ministry of Health. "Plan NP Menopausal Hormone Therapy." BC PharmaCare for Health Professionals. Updated February 11, 2026. Available: www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/plans/national-pharmacare-plan-np/plan-np-menopausal-hormone-therapy
[2] BC Gov News. "BC PharmaCare National Pharmacare Plan launches March 1, 2026." March 1, 2026. Available: news.gov.bc.ca/releases/2026HLTH0018-000197
[3] Health Canada. Notice of Compliance for Duavive (conjugated estrogens/bazedoxifene acetate) issued October 23, 2014. Available: dhpp.hpfb-dgpsa.ca
[4] Astellas Pharma Canada, Inc. Health Canada Notice of Compliance for Veozah (fezolinetant) issued December 2, 2024. Available in Canadian pharmacies from March 18, 2025. Available: newsroom.astellas.com
[5] Bayer Inc. Health Canada Notice of Compliance for Lynkuet (elinzanetant) issued July 23, 2025. OASIS Phase III trials published in JAMA, August 2024. doi:10.1001/jama.2024.11450. Available: bayer.com/en/ca
[6] Vigod SN, et al. "A pragmatic approach to the management of menopause." CMAJ. 2023;195(19):E677–E691. doi:10.1503/cmaj.221438
